Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $36.39, moving +0.94% from the previous trading session.

The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK

by Zacks Equity Research

The Zacks Analyst Blog Highlights: JNJ, Pfizer, AstraZeneca, Sanofi and GSK

Novavax Begins Phase III Study on Coronavirus Vaccine in the UK

by Zacks Equity Research

Novavax (NVAX) starts a phase III efficacy study on its COVID-19 vaccine candidate NVX-CoV2373 in the United Kingdom. Stock rises in after-hours trading.

Pfizer Seeks Xalkori's Label Expansion, Gets Priority Review

by Zacks Equity Research

Pfizer's (PFE) sNDA seeking label expansion of lung cancer drug, Xalkori, for a hematologic indication gets priority review from the FDA.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Coronavirus Vaccine in Phase III, Other Updates

by Kinjel Shah

J&J (JNJ) becomes the fourth company to start a phase III study on its coronavirus vaccine candidate. CHMP recommends approval of several drugs.

Kinjel Shah headshot

4 Coronavirus Vaccine Makers Now in Phase III as J&J Begins Study

by Kinjel Shah

COVID-19 vaccine candidates of four companies - J&J, Pfizer/BioNTech, AstraZeneca/Oxford University and Moderna - are now in late-stage development.

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Axsome Expedites Development Plan for Narcolepsy Candidate

by Zacks Equity Research

Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.

AstraZeneca's Lynparza Gets CHMP Nod for Two New Indications

by Zacks Equity Research

AstraZeneca's (AZN) PARP inhibitor, Lynparza, nears approval as a treatment for prostate cancer, and first-line maintenance treatment for ovarian cancer in combination with Avastin in Europe.

Roche Buys NLRP3 Inflammasome Inhibitors Developer Inflazome

by Zacks Equity Research

Roche (RHHBY) buys Inflazome for ???euro 380 million and gains access to pipeline of small molecule NLRP3 inhibitors.

Kinjel Shah headshot

4 Biotechs That Have More Than Doubled Thanks to Coronavirus

by Kinjel Shah

Stocks of several small biotech companies more than double so far this year as they taste success in their efforts to make a vaccine/medicine for treating COVID-19.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $36.02, moving -1.67% from the previous trading session.

Sweta Killa headshot

Healthcare ETFs, Stocks That Gained Double Digits Last Week

by Sweta Killa

The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.

Ritujay Ghosh headshot

Trump's Pep Talk Raises Vaccine Hopes: 4 Stocks to Watch

by Ritujay Ghosh

Biotech firms and drugmakers across the globe are pumping in millions of dollars to develop a vaccine to wipe out the deadly coronavirus.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals

by Kinjel Shah

AstraZeneca (AZN) resumes its coronavirus vaccine study in the United Kingdom. Merck (MRK) inks two oncology deals with Seattle Genetics.

Mylan/Pfizer's Upjohn Unit Merger on Track to Close in Q4

by Zacks Equity Research

The pending merger of Pfizer's (PFE) Upjohn unit with Mylan (MYL) is on track to close in the fourth quarter of 2020 as almost all necessary regulatory clearances are in place.

Novavax Expands Coronavirus Vaccine Manufacturing Deal in India

by Zacks Equity Research

Novavax (NVAX) amends its present contract with Serum Institute of India Private Limited to widen the manufacturing capacity of its COVID-19 vaccine candidate NVX-CoV2373 to 2 billion plus doses in 2021.

BioNTech Gets New Funding for Coronavirus Vaccine Development

by Zacks Equity Research

BioNTech (BNTX) receives grant of up to almost $445 million to support development and potential approval of its coronavirus vaccine candidate.

Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Pfizer (PFE) closed the most recent trading day at $36.96, moving -0.14% from the previous trading session.

Benjamin Rains headshot

3 Stocks to Buy Now for Growth & Dividends to Counter Low Bond Yields

by Benjamin Rains

Investors might want to consider buying stocks that also provide income via dividends given the current interest rate environment...

Stock Market News for Sep 15, 2020

by Zacks Equity Research

U.S. stock markets closed higher on Monday reversing some of the losses of the last week.

Sweta Killa headshot

ETFs in Focus on Tug of War Between Bulls and Bears

by Sweta Killa

Both bull and bear ETFs are showing immense potential as abrupt changes in sentiments have raised the appeal for these products.

Pfizer Seeks to Raise Coronavirus Study Enrollment Target

by Zacks Equity Research

Pfizer (PFE) and its partner, BioNTech, are seeking FDA's approval to increase enrollment target in the late-stage study on their coronavirus vaccine candidate to diversify patient population.

AstraZeneca Resumes UK Study on Coronavirus Vaccine Candidate

by Zacks Equity Research

AstraZeneca's (AZN) late-stages studies on its COVID-19 vaccine candidate, AZD1222 in U.K. resume after the Medicines Health Regulatory Authority confirms that it is safe to do so.

Kinjel Shah headshot

Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals

by Kinjel Shah

AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.